Previous 10 | Next 10 |
The China National Medical Products Administration ((NMPA)) has approved BeiGene's (BGNE) tislelizumab for use in combination with two chemotherapy regimens as a first-line treatment for patients with advanced squamous non-small cell lung cancer ((NSCLC)).This is the third approval in China f...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that its anti-PD-1 antibody tislelizumab has received approval from the China National Medical Products Administr...
BeiGene (BGNE) has announced a collaboration and license agreement with Novartis Pharma (NVS) for the development, manufacture and commercialization of BeiGene’s anti-PD-1 antibody tislelizumab.Novartis will obtain the development and commercialization rights to tislelizumab in the U.S...
Novartis to co-develop and commercialize tislelizumab in North America, Japan, EU, and six other European countries BeiGene to receive $650 million upfront payment and is eligible to receive up to $1.55 billion in potential regulatory and sales milestone payments plus royaltie...
Privately-held Strand Therapeutics and BeiGene (BGNE) have entered into an option and license agreement for development and commercialization Strand’s mRNA treatments for solid tumors.BeiGene has secured an option to an exclusive license to develop and commercialize in Asia...
Exclusive License Focused on China and Other Key Asia-Pacific Markets Strand Therapeutics, a privately held developer of next-generation, programmable mRNA therapeutics for cancer and other diseases, and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) today announced that they...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the Company will participate in the J.P. Morgan 39th Annual Healthcare Conference on Thursday, January 1...
DXY.cn, a China healthcare platform, raised $500 million in an E round. Zai Lab in-licensed China rights to a next-gen EGFR inhibitor aimed at cells expressing mutant EGFR variants from Boston's Cullinan Oncology in an agreement worth up to $233 million. Hutchison China MediTech a...
Internally-developed anti-PD-1 antibody tislelizumab and BTK inhibitor BRUKINSA ® (zanubrutinib) are included in the NRDL in a total of four approved indications XGEVA ® (denosumab) from BeiGene’s strategic collaboration with Amgen is included in one a...
Pfizer (PFE) has emerged as one of the winners in the race for an effective COVID-19 vaccine. It was the first company to receive commercial authorization from multiple regulatory bodies in the U.S. and throughout the world and began rolling out its vaccine in the U.S. last week. However, the...
News, Short Squeeze, Breakout and More Instantly...
BeiGene Ltd. Company Name:
BGNE Stock Symbol:
NASDAQ Market:
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...
With the earnings season in full swing, these large-cap stocks were the best performers in the last week. Are they in your portfolio? Vertiv Holdi...
Newly released report details Company’s achievements and plans for sustainable growth BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, released its 2023 Responsible Business & Sustainability Report highlighting the Company’s strategy, ...